Log In
BCIQ
Print this Print this
 

Oral nicotine replacement

  Manage Alerts
Collapse Summary General Information
Company Nicogen Inc.
DescriptionOral formulation of CYP2A6 inhibitor combined with a fixed-dose of nicotine
Molecular Target Cytochrome P450 2A6 (CYP2A6)
Mechanism of ActionCytochrome P450 2A6 (CYP2A6) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationAddiction
Indication DetailsSmoking cessation
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today